Physician profile
Chance Wayne Dingler
NPI 1780743898
$2,953.48
in general payments reported to CMS, 2019-2025
30 companies · $134 in 2025
The $134 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $328 · 2020: $260 · 2021: $545 · 2022: $626 · 2023: $655 · 2024: $405 · 2025: $134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,194.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $625.82 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $492.41 | 2019-2025 | |
| Exact Sciences Corporation | $233.70 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $188.42 | 2021-2024 | Ubrelvy |
| Sunovion Pharmaceuticals INC. | $176.52 | 2021-2022 | |
| Corcept Therapeutics | $159.70 | 2024-2025 | Korlym |
| Allergan, INC. | $146.32 | 2019-2022 | |
| Astellas Pharma US INC | $136.57 | 2019-2023 | Veozah |
| Novo Nordisk INC | $120.90 | 2021-2024 | Ozempic, Rybelsus |
| Halozyme INC | $103.24 | 2023 | |
| Antares Pharma, INC. | $74.70 | 2020-2025 | Xyosted |
| Novartis Pharmaceuticals Corporation | $63.66 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $52.81 | 2024 | Voquezna |
| Philips North America LLC | $42.83 | 2020-2021 | |
| Avanir Pharmaceuticals, INC. | $41.80 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $38.56 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $33.29 | 2023 | Quviviq |
| Abbott Laboratories | $26.33 | 2023 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $23.54 | 2023 | |
| Dexcom, INC. | $21.65 | 2023 | Dexcom G6 Transmitter |
| Baxter Healthcare | $18.57 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Horizon Therapeutics Plc | $18.08 | 2019 | |
| Amgen INC. | $17.18 | 2021 | |
| Mylan Specialty L.P. | $15.99 | 2020 | |
| Merck Sharp & Dohme LLC | $14.53 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $14.39 | 2023 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $14.38 | 2019 | |
| Ibsa Pharma INC. | $13.16 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.28 | 2019 | |
| Biomerieux INC | $12.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chance Dingler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.